Global RNA Analysis/Transcriptomics Market to Reach $8.7 Billion by 2027
Amid the COVID-19 crisis, the global market for RNA Analysis/Transcriptomics estimated at US$3.7 Billion in the year 2020, is projected to reach a revised size of US$8.7 Billion by 2027, growing at a CAGR of 13.1% over the analysis period 2020-2027. Microarray, one of the segments analyzed in the report, is projected to record a 11.7% CAGR and reach US$754.9 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the PCR segment is readjusted to a revised 13.7% CAGR for the next 7-year period.
![Global Market for RNA Analysis/Transcriptomics]( "Global Market for RNA Analysis/Transcriptomics")
The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 12.6% CAGR
The RNA Analysis/Transcriptomics market in the U.S. is estimated at US$1.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2027 trailing a CAGR of 12.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.6% and 11.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.5% CAGR.
NGS and Sanger sequencing Segment to Record 14.5% CAGR
In the global NGS and Sanger sequencing segment, USA, Canada, Japan, China and Europe will drive the 14.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$513.2 Million in the year 2020 will reach a projected size of US$1.3 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1 Billion by the year 2027.
Select Competitors (Total 44 Featured):
Amid the COVID-19 crisis, the global market for RNA Analysis/Transcriptomics estimated at US$3.7 Billion in the year 2020, is projected to reach a revised size of US$8.7 Billion by 2027, growing at a CAGR of 13.1% over the analysis period 2020-2027. Microarray, one of the segments analyzed in the report, is projected to record a 11.7% CAGR and reach US$754.9 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the PCR segment is readjusted to a revised 13.7% CAGR for the next 7-year period.
The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 12.6% CAGR
The RNA Analysis/Transcriptomics market in the U.S. is estimated at US$1.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2027 trailing a CAGR of 12.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.6% and 11.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.5% CAGR.
NGS and Sanger sequencing Segment to Record 14.5% CAGR
In the global NGS and Sanger sequencing segment, USA, Canada, Japan, China and Europe will drive the 14.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$513.2 Million in the year 2020 will reach a projected size of US$1.3 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1 Billion by the year 2027.
Select Competitors (Total 44 Featured):
- Affymetrix, Inc.
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche AG
- Fluidigm Corporation
- GE Healthcare
- Illumina, Inc.
- MilliporeSigma
- Qiagen NV
- Thermo Fisher Scientific, Inc.
Frequently Asked Questions about the Global Market for RNA Analysis/Transcriptomics
What is the estimated value of the Global Market for RNA Analysis/Transcriptomics?
The Global Market for RNA Analysis/Transcriptomics was estimated to be valued at $3.7 Billion in 2020.
What is the growth rate of the Global Market for RNA Analysis/Transcriptomics?
The growth rate of the Global Market for RNA Analysis/Transcriptomics is 13.0%, with an estimated value of $8.7 Billion by 2027.
What is the forecasted size of the Global Market for RNA Analysis/Transcriptomics?
The Global Market for RNA Analysis/Transcriptomics is estimated to be worth $8.7 Billion by 2027.
| Report Attribute | Details |
|---|---|
| No. of Pages | 178 |
| Published | April 2021 |
| Forecast Period | 2020 - 2027 |
| Estimated Market Value ( USD | $ 3.7 Billion |
| Forecasted Market Value ( USD | $ 8.7 Billion |
| Compound Annual Growth Rate | 13.0% |
| Regions Covered | Global |
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Current & Future Analysis for RNA Analysis/Transcriptomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 2: World 7-Year Perspective for RNA Analysis/Transcriptomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
- Table 3: World Current & Future Analysis for Microarray by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 4: World 7-Year Perspective for Microarray by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
- Table 5: World Current & Future Analysis for PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 6: World 7-Year Perspective for PCR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
- Table 7: World Current & Future Analysis for NGS and Sanger Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 8: World 7-Year Perspective for NGS and Sanger Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
- Table 9: World Current & Future Analysis for RNAi by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 10: World 7-Year Perspective for RNAi by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
- Table 11: World Current & Future Analysis for Clinical Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 12: World 7-Year Perspective for Clinical Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
- Table 13: World Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 14: World 7-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
- Table 15: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 16: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
- Table 17: World Current & Future Analysis for Academic Research and Government Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 18: World 7-Year Perspective for Academic Research and Government Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
- Table 19: World Current & Future Analysis for Pharmaceutical and Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 20: World 7-Year Perspective for Pharmaceutical and Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
- Table 21: World Current & Future Analysis for Hospitals and Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 22: World 7-Year Perspective for Hospitals and Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
III. MARKET ANALYSIS
- UNITED STATES
- Table 23: USA Current & Future Analysis for RNA Analysis/Transcriptomics by Technology - Microarray, PCR, NGS and Sanger Sequencing and RNAi - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 24: USA 7-Year Perspective for RNA Analysis/Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray, PCR, NGS and Sanger Sequencing and RNAi for the Years 2020 & 2027
- Table 25: USA Current & Future Analysis for RNA Analysis/Transcriptomics by Application - Clinical Diagnostics, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 26: USA 7-Year Perspective for RNA Analysis/Transcriptomics by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug Discovery and Other Applications for the Years 2020 & 2027
- Table 27: USA Current & Future Analysis for RNA Analysis/Transcriptomics by End-Use - Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 28: USA 7-Year Perspective for RNA Analysis/Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers for the Years 2020 & 2027
- CANADA
- Table 29: Canada Current & Future Analysis for RNA Analysis/Transcriptomics by Technology - Microarray, PCR, NGS and Sanger Sequencing and RNAi - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 30: Canada 7-Year Perspective for RNA Analysis/Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray, PCR, NGS and Sanger Sequencing and RNAi for the Years 2020 & 2027
- Table 31: Canada Current & Future Analysis for RNA Analysis/Transcriptomics by Application - Clinical Diagnostics, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 32: Canada 7-Year Perspective for RNA Analysis/Transcriptomics by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug Discovery and Other Applications for the Years 2020 & 2027
- Table 33: Canada Current & Future Analysis for RNA Analysis/Transcriptomics by End-Use - Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 34: Canada 7-Year Perspective for RNA Analysis/Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers for the Years 2020 & 2027
- JAPAN
- Table 35: Japan Current & Future Analysis for RNA Analysis/Transcriptomics by Technology - Microarray, PCR, NGS and Sanger Sequencing and RNAi - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 36: Japan 7-Year Perspective for RNA Analysis/Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray, PCR, NGS and Sanger Sequencing and RNAi for the Years 2020 & 2027
- Table 37: Japan Current & Future Analysis for RNA Analysis/Transcriptomics by Application - Clinical Diagnostics, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 38: Japan 7-Year Perspective for RNA Analysis/Transcriptomics by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug Discovery and Other Applications for the Years 2020 & 2027
- Table 39: Japan Current & Future Analysis for RNA Analysis/Transcriptomics by End-Use - Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 40: Japan 7-Year Perspective for RNA Analysis/Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers for the Years 2020 & 2027
- CHINA
- Table 41: China Current & Future Analysis for RNA Analysis/Transcriptomics by Technology - Microarray, PCR, NGS and Sanger Sequencing and RNAi - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 42: China 7-Year Perspective for RNA Analysis/Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray, PCR, NGS and Sanger Sequencing and RNAi for the Years 2020 & 2027
- Table 43: China Current & Future Analysis for RNA Analysis/Transcriptomics by Application - Clinical Diagnostics, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 44: China 7-Year Perspective for RNA Analysis/Transcriptomics by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug Discovery and Other Applications for the Years 2020 & 2027
- Table 45: China Current & Future Analysis for RNA Analysis/Transcriptomics by End-Use - Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 46: China 7-Year Perspective for RNA Analysis/Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers for the Years 2020 & 2027
- EUROPE
- Table 47: Europe Current & Future Analysis for RNA Analysis/Transcriptomics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 48: Europe 7-Year Perspective for RNA Analysis/Transcriptomics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
- Table 49: Europe Current & Future Analysis for RNA Analysis/Transcriptomics by Technology - Microarray, PCR, NGS and Sanger Sequencing and RNAi - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 50: Europe 7-Year Perspective for RNA Analysis/Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray, PCR, NGS and Sanger Sequencing and RNAi for the Years 2020 & 2027
- Table 51: Europe Current & Future Analysis for RNA Analysis/Transcriptomics by Application - Clinical Diagnostics, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 52: Europe 7-Year Perspective for RNA Analysis/Transcriptomics by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug Discovery and Other Applications for the Years 2020 & 2027
- Table 53: Europe Current & Future Analysis for RNA Analysis/Transcriptomics by End-Use - Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 54: Europe 7-Year Perspective for RNA Analysis/Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers for the Years 2020 & 2027
- FRANCE
- Table 55: France Current & Future Analysis for RNA Analysis/Transcriptomics by Technology - Microarray, PCR, NGS and Sanger Sequencing and RNAi - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 56: France 7-Year Perspective for RNA Analysis/Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray, PCR, NGS and Sanger Sequencing and RNAi for the Years 2020 & 2027
- Table 57: France Current & Future Analysis for RNA Analysis/Transcriptomics by Application - Clinical Diagnostics, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 58: France 7-Year Perspective for RNA Analysis/Transcriptomics by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug Discovery and Other Applications for the Years 2020 & 2027
- Table 59: France Current & Future Analysis for RNA Analysis/Transcriptomics by End-Use - Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 60: France 7-Year Perspective for RNA Analysis/Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers for the Years 2020 & 2027
- GERMANY
- Table 61: Germany Current & Future Analysis for RNA Analysis/Transcriptomics by Technology - Microarray, PCR, NGS and Sanger Sequencing and RNAi - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 62: Germany 7-Year Perspective for RNA Analysis/Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray, PCR, NGS and Sanger Sequencing and RNAi for the Years 2020 & 2027
- Table 63: Germany Current & Future Analysis for RNA Analysis/Transcriptomics by Application - Clinical Diagnostics, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 64: Germany 7-Year Perspective for RNA Analysis/Transcriptomics by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug Discovery and Other Applications for the Years 2020 & 2027
- Table 65: Germany Current & Future Analysis for RNA Analysis/Transcriptomics by End-Use - Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 66: Germany 7-Year Perspective for RNA Analysis/Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers for the Years 2020 & 2027
- ITALY
- Table 67: Italy Current & Future Analysis for RNA Analysis/Transcriptomics by Technology - Microarray, PCR, NGS and Sanger Sequencing and RNAi - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 68: Italy 7-Year Perspective for RNA Analysis/Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray, PCR, NGS and Sanger Sequencing and RNAi for the Years 2020 & 2027
- Table 69: Italy Current & Future Analysis for RNA Analysis/Transcriptomics by Application - Clinical Diagnostics, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 70: Italy 7-Year Perspective for RNA Analysis/Transcriptomics by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug Discovery and Other Applications for the Years 2020 & 2027
- Table 71: Italy Current & Future Analysis for RNA Analysis/Transcriptomics by End-Use - Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 72: Italy 7-Year Perspective for RNA Analysis/Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers for the Years 2020 & 2027
- UNITED KINGDOM
- Table 73: UK Current & Future Analysis for RNA Analysis/Transcriptomics by Technology - Microarray, PCR, NGS and Sanger Sequencing and RNAi - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 74: UK 7-Year Perspective for RNA Analysis/Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray, PCR, NGS and Sanger Sequencing and RNAi for the Years 2020 & 2027
- Table 75: UK Current & Future Analysis for RNA Analysis/Transcriptomics by Application - Clinical Diagnostics, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 76: UK 7-Year Perspective for RNA Analysis/Transcriptomics by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug Discovery and Other Applications for the Years 2020 & 2027
- Table 77: UK Current & Future Analysis for RNA Analysis/Transcriptomics by End-Use - Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 78: UK 7-Year Perspective for RNA Analysis/Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers for the Years 2020 & 2027
- REST OF EUROPE
- Table 79: Rest of Europe Current & Future Analysis for RNA Analysis/Transcriptomics by Technology - Microarray, PCR, NGS and Sanger Sequencing and RNAi - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 80: Rest of Europe 7-Year Perspective for RNA Analysis/Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray, PCR, NGS and Sanger Sequencing and RNAi for the Years 2020 & 2027
- Table 81: Rest of Europe Current & Future Analysis for RNA Analysis/Transcriptomics by Application - Clinical Diagnostics, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 82: Rest of Europe 7-Year Perspective for RNA Analysis/Transcriptomics by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug Discovery and Other Applications for the Years 2020 & 2027
- Table 83: Rest of Europe Current & Future Analysis for RNA Analysis/Transcriptomics by End-Use - Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 84: Rest of Europe 7-Year Perspective for RNA Analysis/Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers for the Years 2020 & 2027
- ASIA-PACIFIC
- Table 85: Asia-Pacific Current & Future Analysis for RNA Analysis/Transcriptomics by Technology - Microarray, PCR, NGS and Sanger Sequencing and RNAi - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 86: Asia-Pacific 7-Year Perspective for RNA Analysis/Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray, PCR, NGS and Sanger Sequencing and RNAi for the Years 2020 & 2027
- Table 87: Asia-Pacific Current & Future Analysis for RNA Analysis/Transcriptomics by Application - Clinical Diagnostics, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 88: Asia-Pacific 7-Year Perspective for RNA Analysis/Transcriptomics by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug Discovery and Other Applications for the Years 2020 & 2027
- Table 89: Asia-Pacific Current & Future Analysis for RNA Analysis/Transcriptomics by End-Use - Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 90: Asia-Pacific 7-Year Perspective for RNA Analysis/Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers for the Years 2020 & 2027
- REST OF WORLD
- Table 91: Rest of World Current & Future Analysis for RNA Analysis/Transcriptomics by Technology - Microarray, PCR, NGS and Sanger Sequencing and RNAi - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 92: Rest of World 7-Year Perspective for RNA Analysis/Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray, PCR, NGS and Sanger Sequencing and RNAi for the Years 2020 & 2027
- Table 93: Rest of World Current & Future Analysis for RNA Analysis/Transcriptomics by Application - Clinical Diagnostics, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 94: Rest of World 7-Year Perspective for RNA Analysis/Transcriptomics by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug Discovery and Other Applications for the Years 2020 & 2027
- Table 95: Rest of World Current & Future Analysis for RNA Analysis/Transcriptomics by End-Use - Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 96: Rest of World 7-Year Perspective for RNA Analysis/Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Academic Research and Government Institutes, Pharmaceutical and Biotech Companies and Hospitals and Diagnostic Centers for the Years 2020 & 2027
IV. COMPETITION
- Total Companies Profiled: 44
